Table 1.
Susceptibility Results Involving Enterobacteriaceae from the 2017 Surveillance Collection and the 2013–2014 Carbapenem-Resistant Collection
| MIC50 |
MIC90 |
Range |
|
|
|---|---|---|---|---|
| mg/L | Susceptible, % | |||
| 2017 surveillance isolates | ||||
| Escherichia coli (n = 1869) | ||||
| Cefiderocol | 0.12 | 0.5 | ≤0.03 to 2 | 100 |
| Piperacillin/tazobactam | 2/4 | 4/4 | ≤0.25/4 to >128/4 | 99 |
| Ceftriaxone | ≤0.06 | 16 | ≤0.06 to >32 | 88 |
| Ceftazidime | 0.25 | 2 | ≤0.12 to >32 | 92 |
| Meropenem | ≤0.12 | ≤0.12 | ≤0.12 to 4 | 99.9 |
| Gentamicin | 1 | >16 | ≤0.25 to >16 | 86 |
| TMP/SMX | ≤0.25/4.75 | >4/76 | ≤0.25/4.75 to >4/76 | 64 |
| Ciprofloxacin | ≤0.12 | >4 | ≤0.12 to >4 | 67 |
| Enterobacter spp. (n = 172) | ||||
| Cefiderocol | 0.12 | 0.5 | ≤0.03 to 1 | 100 |
| Piperacillin/tazobactam | 4/4 | 32/4 | ≤0.25/4 to >128/4 | 90 |
| Ceftriaxone | 0.25 | 32 | ≤0.06 to >32 | 81 |
| Ceftazidime | 0.5 | 32 | ≤0.12 to >32 | 83 |
| Meropenem | ≤0.12 | ≤0.12 | ≤0.12 to >8 | 98 |
| Gentamicin | 1 | 1 | ≤0.25 to >16 | 94 |
| TMP/SMX | ≤0.25/4.75 | >4/76 | ≤0.25/4.75 to >4/76 | 84 |
| Ciprofloxacin | ≤0.12 | 1 | ≤0.12 to >4 | 91 |
| Klebsiella pneumoniae (n = 517) | ||||
| Cefiderocol | 0.12 | 0.5 | ≤0.03 to 2 | 100 |
| Piperacillin/tazobactam | 4/4 | 8/4 | ≤0.25/4 to >128/4 | 96 |
| Ceftriaxone | ≤0.06 | >32 | ≤0.06 to >32 | 83 |
| Ceftazidime | 0.25 | 16 | ≤0.12 to >32 | 84 |
| Meropenem | ≤0.12 | ≤0.12 | ≤0.12 to >8 | 96 |
| Gentamicin | 0.5 | 8 | ≤0.25 to >16 | 89 |
| TMP/SMX | ≤0.25/4.75 | >4/76 | ≤0.25/4.75 to >4/76 | 79 |
| Ciprofloxacin | ≤0.12 | >4 | ≤0.12 to >4 | 85 |
| 2013–2014 Carbapenem-resistant surveillance isolates | ||||
| K. pneumoniae (n = 111) | ||||
| Cefiderocol | 1 | 2 | ≤0.03 to 4 | 100 |
TMP/SMX, trimethoprim sulfamethoxazole.